Moreover, the tolerability of an enzymatically active ACE2-based therapeutic agent was already demonstrated in healthy subjects (61) and patients with acute respiratory distress syndrome (62), pulmonary arterial hypertension (63), or COVID-19 (64). This evidence concerns the gene ACE2 and acute respiratory distress syndrome.